Prognostic factors in follicular lymphoma: The importance of beta-2 microglobulin

Tumori

Volumn 96, Issue 1, 2010, Pages 117-121

  Cánovas, Araceli ^a   Alonso, Juan J ^a   Barreiro, Guillermo ^a   Aguirre, Ciriaco ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Beta 2 microglobulin; FLIPI; Follicular lymphoma; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; COHORT ANALYSIS; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK; SYMPTOM; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77950828018     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600119     Document Type: Article

References (21)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 20: 75-80, 1993.
2. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo- López AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol, 22: 4711-4716, 2004.
3. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23: 8447-8452, 2005.
4. Schmitz N, Buske C, Gisselbrecht C: Autologous stem cell transplantation in lymphoma. Sem Hematol, 44: 234-345, 2007.
5. Luminari S, Federico M: Prognosis of follicular lymphomas. Hematol Oncol, 24: 64-72, 2006.
6. Solal-Céligny P, Roy P, Colombat P,White J, Armitage JO, Arranz- Saez R, AuWY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-García E, Doyen CH, Federico M, Fisher R, García- Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, López-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, SoubeyranHT,VitoloU, Zinzani PL, Zucca E,Monserrat E: Follicular Lymphoma International Prognostic Index. Blood, 104: 1258-1265, 2004.
7. Plancarte F, López-Guillermo A, Arenillas L,Montoto S,Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E,Monserrat E: Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol, 76: 58-63, 2006.
8. Rodriguez J, Cabanillas F, McLaughlin P, Swan F, Rodriguez M, Hagemeister F, Romaguera J: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the "tumor score". Ann Oncol, 3: 711-717, 1992.
9. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Study Group. J Clin Oncol, 17: 1244-1253, 1999.
10. Cox DR: Regression model and life tables. J Am Stat Assoc, 34: 187-220, 1972.
11. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc, 53: 457-481, 1958.
12. Cabanillas F, RodriguezMA, Swan F Jr: Recent trends in the management of lymphoma atM.D. Anderson Cancer Center. Sem Oncol, 17 (6 Suppl 10): 28-32, 1990.
13. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M,Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, UnterhaltM: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106: 3725-3732, 2005.
14. HeroldM, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Nauman R, KnaufW, FreundM, Rohberg R, Höffken K, Franke A, Ittel T, Kettner E,Haak U,MeyU, Klinkenstein C, Assmann M, von Grünhagen: Rituximab added to first line mitoxantrone, chlorambucil, and prednisone followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol, 25: 1986-1992, 2007.
15. Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice C, Mahé B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: result of the GELA-GOELAMS FL2000 study. Blood, 112: 4824-4831, 2008.
16. Czuczman MS, Grillo-López AJ, Alkuzweny B, Weaver R, Larocca A: Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma, 47: 1830-1840, 2006.
17. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk fromintermediate- or low -risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with respect to treatment outcome. Blood, 108:1504-1508, 2006.
18. SanMiguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H,Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I,Westin J: International Staging System for multiple myeloma. J Clin Oncol, 23: 3412-3420, 2005.
19. Johnson PW, Whelan J, Longhurst S, Stepniewska K, Matthews J, Amess J, Norton A, Rohatiner AZ, Lister TA: Beta- 2 microglobulin: a prognostic factor in diffuse aggressive non Hodgkin's lymphomas. Br J Cancer, 67: 792-797, 1993.
20. DimopoulosMA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB: Prognostic role of serum beta-2 microglobulin in Hodgkin's disease. J Clin Oncol, 11: 1108-1111, 1993.
21. Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gianelli U, Maiorana A, Merli F, Bellei M, Pozzi S, Stelitano C, Lazzaro A, Gobbi PG, Baldini L, Bergantini S, Fregoni V, Brugiatelli M: Prognostic relevance of serum beta- 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens: A GISL study. Haematologica, 92: 1482-1488, 2007.